Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Asieris Enters $73 Million Agreement for Global Rights to Cervical Lesion Treatment

publication date: Jul 2, 2019

Asieris MediTech of Taizhou acquired global rights to Cevira®, a treatment for HPV-induced precancerous cervical lesions, from Photocure of Oslo in an agreement worth up to $73 million. Cevira® is a photodynamic drug-device combination that treats cervical dysplasia by placing the device on the patient's cervix during an office procedure. Asieris will pay a $5 million signing fee, with $54 million for milestones in China, US and EU development, and $14 million for approval of a second China indication. More details....

Stock Symbol: (OSE: PHO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.